Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines
- 1 December 2003
- journal article
- Published by Springer Nature in Oncogene
- Vol. 23 (4) , 1010-1013
Abstract
Herceptin is a humanized monoclonal antibody targeted against the extracellular domain of the HER2 oncogene, which is amplified and overexpressed in 10–34% of breast cancers. Herceptin therapy provides effective treatment in HER2-positive metastatic breast cancer, although a favorable treatment response is not achieved in all cases. Here, we show that Herceptin treatment induces a dose-dependent growth reduction in breast cancer cell lines with HER2 amplification, whereas nonamplified cell lines are practically resistant. Time-course analysis of global gene expression patterns in amplified and nonamplified cell lines indicated a major change in transcript levels between 24 and 48 h of Herceptin treatment. A step-wise gene selection algorithm revealed a set of 439 genes whose temporal expression profiles differed most between the amplified and nonamplified cell lines. The discriminatory power of these genes was confirmed by both hierarchical clustering and self-organizing map analyses. In the amplified cell lines, the Herceptin treatment induced the expression of several genes involved in RNA processing and DNA repair, while cell adhesion mediators and known oncogenes, such as c-FOS and c-KIT, were downregulated. These results provide additional clues to the downstream effects of blocking the HER2 pathway in breast cancer and may provide new targets for more effective treatment.Keywords
This publication has 20 references indexed in Scilit:
- Estrogen regulation of c-fos gene expression through phosphatidylinositol-3-kinase-dependent activation of serum response factor in MCF-7 breast cancer cellsBiochemical and Biophysical Research Communications, 2002
- Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancerProceedings of the National Academy of Sciences, 2001
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapySeminars in Cancer Biology, 1999
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998
- Ratio-based decisions and the quantitative analysis of cDNA microarray imagesJournal of Biomedical Optics, 1997
- Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.Journal of Clinical Investigation, 1993
- Humanization of an anti-p185HER2 antibody for human cancer therapy.Proceedings of the National Academy of Sciences, 1992
- Direct effects of estrogen on c-fos and c-myc protooncogene expression and cellular proliferation in human breast cancer cellsMolecular and Cellular Endocrinology, 1989
- Robust Locally Weighted Regression and Smoothing ScatterplotsJournal of the American Statistical Association, 1979